ClinicalTrials.gg
Status unknownNCT05161039Updated Jun 9, 2022

Serranator Recoil Study

An interventional study of Serranator and POBA in Peripheral Arterial Disease and Critical Limb Ischemia, sponsored by Cagent Vascular LLC. Status unknown at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-09.

Primary conditionChronic Limb-Threatening IschemiaRegistry: Peripheral Arterial DiseaseReclassifiedWhy we changed it
Registry
Peripheral Arterial Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Chronic Limb-Threatening Ischemia
Why
  1. The study's listed conditions name Chronic Limb-Threatening Ischemia, a narrower term within Peripheral Arterial Disease.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Cagent Vascular LLC · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 105 studies in Chronic Limb-Threatening Ischemia with a site in United States — 13 open to participants now, 20 under way, 2 of them phase 3. Chronic Limb-Threatening Ischemia · United States.

Planned enrollment
55th of 82
20 · median 38
Started
2021
with 2 others
No phase
38 of 105
8 open now
Registered
88th of 105
by date
Lead sponsor
2 of 105
Cagent Vascular LLC

Among the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, this one is the 55th largest by planned enrollment of the 82 interventional ones that give a count, is one of 3 that started in 2021, is one of 38 with no phase, and was the 88th registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

13 of the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, or all of them as a file.
02

Study summary

The study objective is to assess the ability to define and measure post treatment recoil in infrapopliteal arteries. Preliminary evidence as to the differences between serration angioplasty and standard balloon angioplasty as defined by post treatment recoil, lumen gain, and dissection will be collected.

Read the detailed description

Multi-center, feasibility study treating up to 20 atherosclerotic lesions in the infrapopliteal arteries. The study will capture angiographic imaging (pre, during, post, and post 15 mins) for all lesions, and a subset (up to 10) of IVUS imaging data (pre, post, and post 15 mins), to compare serration angioplasty vs standard angioplasty and its effects on vessel recoil and final diameter stenosis.

03

Conditions studied

  • Peripheral Arterial Disease
  • Critical Limb Ischemia

Browse trials for

04

In context

Chronic Limb-Threatening Ischemia Reclassified

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

This study's planned enrollment of 20 is below the median of 41 across 240 interventional studies indexed under Chronic Limb-Threatening Ischemia.

Browse Chronic Limb-Threatening Ischemia studies →

Lead sponsor

Cagent Vascular LLC is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Compared within Chronic Limb-Threatening Ischemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Peripheral Arterial Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female of >18 years old.
  2. Women of must have a negative urine pregnancy test within 7 days of index procedure.
  3. Subject or subject's legal representative has been informed of the nature of the study, agrees to participate, and comply, and has signed the consent form.
  4. Subject has Rutherford Clinical Category 3, 4, 5, or 6.

Angiographic Inclusion Criteria:

  1. Target lesion(s) has stenosis >70% by visual assessment;
  2. De-novo, or non-stented re-stenotic lesions;
  3. Reference vessel diameter is between 2.5 mm and 3.5 mm, inclusive;
  4. Target lesions involve infrapopliteal tibial arteries including pedal;
  5. A target lesion may consist of one long or multiple serial lesions that are up to and including 12 cm in length;
  6. If a second lesion is identified in another vessel, the second lesion can also be treated and if treated will be treated with the alternate treatment.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of aneurysm or acute thrombus in the target vessel.
  2. Subject has an allergy to contrast medium that cannot be pretreated.
  3. Subject is pregnant or breastfeeding.

Angiographic Exclusion Criteria:

  1. Acute Total Occlusions; evidence of acute thrombus formation by angiography.
  2. In-stent restenotic lesions.
  3. Inability to cross the lesion with the assigned study device.
  4. Treatment of target lesion with atherectomy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Other
    Serranator

    Device: Serranator

  • Other
    POBA

    Device: POBA

Interventions

  • DeviceSerranator

    Serranator® PTA Serration Balloon Catheter manufactured by Cagent Vascular

  • DevicePOBA

    Plain balloon angioplasty device

07

What researchers measure

Primary outcomes

  1. Presence of post treatment recoil

    Obtain preliminary data on post treatment recoil in infrapopliteal arteries utilizing angiographic and IVUS data following serration angioplasty and standard angioplasty.

    Time frame: 15 minutes post procedure

08

Study locations

2 of 2 sites recruiting
  • Stanford University
    Palo Alto, California 94305, United States
    Recruiting
    • Venita Chandra, MD · Contact
  • Klinik für Angiologie, Klinikum Hochsauerland GmbH
    Arnsberg, Germany
    Recruiting
    • Stefan Stahlhoff, MD · Contact
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Jul 2022, 8 months after the start.

Of 72 interventional studies with no phase under Chronic Limb-Threatening Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 85. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2021
First posted
Dec 16, 2021
StartActual
Nov 15, 2021
Primary completionEst.
Jul 2022
CompletionEst.
Jul 2022
Last update
Jun 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05161039
Lead sponsor
Cagent Vascular LLC
Responsible party
Sponsor
First posted
Dec 16, 2021
Start date
Nov 15, 2021
Primary completion
Jul 2022 (estimated)
Completion
Jul 2022 (estimated)
Last update
Jun 9, 2022

Study contacts

Robert Giasolli
Contact
rgiasolli@cagentvascular.com
610.688.2006

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion